BMO Capital Maintains Outperform on National Health Investors, Lowers Price Target to $80
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
BMO Capital analyst Juan Sanabria maintains National Health Investors (NYSE:NHI) with a Outperform and lowers the price target from $90 to $80.
BMO Capital analyst Juan Sanabria maintains National Health Investors (NYSE:NHI) with a Outperform and lowers the price target from $90 to $80.